Sertraline and Pacritinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Sertraline
No brand names on recordPacritinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of your medicines can gently affect your heart's rhythm. Sertraline (an antidepressant) and pacritinib (Vonjo, used for a bone marrow condition) can each stretch out a part of the heartbeat called the QT interval. When taken together, that effect can add up, which in rare cases could lead to an irregular heartbeat.
This concern is based on how these drugs work rather than lots of real-world reports, so try not to worry. The good news is your care team can manage this easily by checking your heart tracing (an EKG), keeping your potassium and other minerals in a healthy range, and adjusting things if needed. Please don't stop either medicine on your own, just talk with your pharmacist or doctor.
Effect: Additive QTc prolongation, increasing torsades/arrhythmia risk. Both agents are independent QT-prolonging drugs; neither is a prodrug relevant here, so this is a pharmacodynamic (additive), not pharmacokinetic, interaction.
Direction/magnitude: Additive PD effect; magnitude not quantified. Evidence: theoretical. Onset: unspecified. Severity: major.
Management:
- Avoid pacritinib if baseline QTc >480 msec.
- Obtain baseline and periodic ECG; monitor electrolytes.
- Correct hypokalemia/hypomagnesemia before and during therapy.
- Hold pacritinib if QTc >500 msec or increases >60 msec from baseline; resume at same dose if resolved to
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Do not administer pacritinib together with any agent recognized for prolonging the QTc interval. When drugs that prolong the QT interval are used concurrently, their effects may be additive to the QTc-prolonging action of pacritinib, thereby raising the likelihood of cardiac arrhythmias. In patients whose baseline QTc exceeds 480 msec, pacritinib should be avoided. Should QT interval prolongation exceed 500 msec, or increase by more than 60 msec relative to baseline, pacritinib must be held. Pacritinib may be resumed at the same dose if the QTc prolongation returns to 480 msec or less, or to baseline, within 1 week. When resolution takes longer than 1 week, pacritinib should be restarted at a reduced dose. In situations where such coadministration cannot be avoided, correct hypokalemia both before and throughout pacritinib therapy, and address QTc prolongation through interruption of pacritinib and electrolyte management1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Your care team can manage this safely with a few standard steps. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise.
- Your team may check an EKG before and during treatment to watch your heart rhythm.
- They may check blood minerals like potassium and magnesium and correct any that are low.
- If your QT reading rises too much, pacritinib may be paused and restarted, with the dose individualized by your team.
Tell your pharmacist or doctor if you feel fainting, dizziness, palpitations, or a racing/irregular heartbeat. Also mention any other medicines that affect heart rhythm.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Sertraline and Pacritinib together?
Taking sertraline with pacritinib can add together to affect your heart rhythm (QT interval), so your care team may check EKGs and electrolytes and adjust pacritinib if needed. Keep taking both as prescribed and report any fainting or palpitations. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Sertraline and Pacritinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Sertraline and Pacritinib interaction managed?
Your care team can manage this safely with a few standard steps. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Your team may check an EKG before and during treatment to watch your heart rhythm. They may check blood minerals like potassium and magnesium and correct any that are low. If your QT reading rises too much, pacritinib may be paused and restar… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Sertraline or Pacritinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VONJO(R) oral capsules, pacritinib oral capsules. CTI BioPharma Corp (per FDA), Seattle, WA, 2024. DailyMed
Keep reading about Sertraline
Keep reading about Pacritinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist